74.24
Lantheus Holdings Inc stock is traded at $74.24, with a volume of 1.33M.
It is down -1.97% in the last 24 hours and up +0.86% over the past month.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
See More
Previous Close:
$75.73
Open:
$75.48
24h Volume:
1.33M
Relative Volume:
1.38
Market Cap:
$4.80B
Revenue:
$1.54B
Net Income/Loss:
$233.56M
P/E Ratio:
22.05
EPS:
3.3669
Net Cash Flow:
$348.64M
1W Performance:
-7.72%
1M Performance:
+0.86%
6M Performance:
+39.47%
1Y Performance:
-25.34%
Lantheus Holdings Inc Stock (LNTH) Company Profile
Name
Lantheus Holdings Inc
Sector
Phone
978 671-8001
Address
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
Compare LNTH vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
LNTH
Lantheus Holdings Inc
|
74.24 | 4.80B | 1.54B | 233.56M | 348.64M | 3.3669 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-12-25 | Upgrade | Truist | Hold → Buy |
| Oct-08-25 | Downgrade | Goldman | Buy → Neutral |
| Aug-12-25 | Downgrade | Truist | Buy → Hold |
| Dec-18-24 | Initiated | Goldman | Buy |
| Sep-03-24 | Initiated | Redburn Atlantic | Buy |
| Jul-10-24 | Reiterated | JMP Securities | Mkt Outperform |
| Dec-18-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-04-23 | Initiated | TD Cowen | Outperform |
| Sep-29-23 | Initiated | William Blair | Outperform |
| Mar-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Nov-30-22 | Initiated | SVB Leerink | Outperform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| May-09-22 | Initiated | B. Riley Securities | Buy |
| Apr-13-22 | Initiated | Truist | Buy |
| Feb-01-21 | Initiated | SVB Leerink | Outperform |
| Jun-29-20 | Resumed | Jefferies | Buy |
| Aug-16-19 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Nov-02-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-08-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-23-16 | Resumed | Credit Suisse | Neutral |
| Feb-24-16 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-11-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-30-15 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-20-15 | Initiated | Credit Suisse | Outperform |
| Jul-20-15 | Initiated | Jefferies | Buy |
| Jul-20-15 | Initiated | RBC Capital Mkts | Outperform |
| Jul-20-15 | Initiated | Robert W. Baird | Outperform |
| Jul-20-15 | Initiated | Wells Fargo | Outperform |
View All
Lantheus Holdings Inc Stock (LNTH) Latest News
William Blair, Jefferies Maintain LNTH Lantheus Holdings March 2026: Outperform Buy - Meyka
Nuclear Medicine (Radiopharmaceuticals) Market Set for Strong Growth at 9.50% CAGR Through 2034: DelveInsight | Lantheus, GE Healthcare, Novartis, Sotera Health and Others - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
CWA Asset Management Group LLC Makes New $1.67 Million Investment in Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus Holdings, Inc. (LNTH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lantheus to sell SPECT Business to SHINE Technologies - MSN
LNTH Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges LNTH Investors with Losses to Contact the Firm - The National Law Review
Class Action Announcement for Lantheus Holdings, Inc. Investors - The National Law Review
Form DEF 14A LANTHEUS HOLDINGS For: 20 March - Investing.com
Lantheus Holdings, Inc. ($LNTH) Former CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Lantheus Holdings, Inc. SEC Filing - Stock Titan
Lantheus (NASDAQ: LNTH) 2026 proxy outlines board elections, pay and equity plan - Stock Titan
Lantheus says FDA extended review period for radioactive diagnostic kit - MSN
How Lantheus Holdings Inc. (LNTH) Affects Rotational Strategy Timing - Stock Traders Daily
Lantheus Holdings Inc (LNTH) Trading Down 3.37% on Mar 19 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Investors to Connect - ACCESS Newswire
Aug Weekly: Will Lantheus Holdings Inc outperform the market in YEAR2026 Key Highlights & Scalable Portfolio Growth Methods - baoquankhu1.vn
Why Lantheus Holdings Stock Popped by Almost 12% Last Month - AOL.com
Lantheus price target raised to $82 from $80 at Truist - MSN
Lantheus Holdings Q4 2025 earnings preview - MSN
Citizens reiterates Lantheus stock rating after FDA extends review By Investing.com - Investing.com Canada
FDA extends review of Lantheus’ neuroendocrine tumor drug By Investing.com - Investing.com South Africa
Lantheus Holdings Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Lantheus says FDA pushed deadline for reviewing its tumor diagnostic kit application - MSN
Lantheus Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Lantheus stock holds Outperform at William Blair after FDA delay By Investing.com - Investing.com India
Lantheus stock holds Outperform at William Blair after FDA delay - Investing.com
Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application - Asianet Newsable
Lantheus (LNTH) Drug Application Review Extended by FDA - GuruFocus
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs) - Bitget
Jefferies Maintains Buy on Lantheus Holdings (LNTH) Mar 17 2026 - Meyka
US FDA extends review of Lantheus' diagnostic imaging kit by three months - Yahoo Finance
FDA extends review of Lantheus’ neuroendocrine tumor drug - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Jefferies raises Lantheus stock price target on PSMA PET outlook By Investing.com - Investing.com Canada
Lantheus Holdings Inc Stock (ISIN: US5156731020) Faces Pressure as Farallon Sells 3.245 Million Shar - AD HOC NEWS
US FDA extends review of Lantheus’ diagnostic imaging kit by three months - 1470 & 100.3 WMBD
Farallon Capital Management LLC Sells 3,245,000 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat
2026-03-15 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Investors to Learn More About the Investigation | NDAQ:LNTH | Press Release - Stockhouse
Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Lantheus (NASDAQ:LNTH) Lowered to Buy Rating by Wall Street Zen - MarketBeat
How does Lantheus Holdings Inc compare to its peersLayoff News & Community Consensus Trade Alerts - baoquankhu1.vn
FDA approves Lantheus’ PYLARIFY TruVu for prostate cancer imaging - Investing.com Nigeria
Portolan Capital Management LLC Purchases 42,731 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus Secures Two FDA Milestones in Four Days: Lutathera Radioequivalent and PSMA PET Upgrade - Oncodaily
Lantheus Holdings (LNTH) Is Up 5.4% After New PYLARIFY TruVu And LUTATHERA ApprovalsHas The Bull Case Changed? - simplywall.st
Why Lantheus (LNTH) Is Up 5.4% After Dual FDA Wins In Radiopharmaceutical Oncology Expansion - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Stockholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Lantheus Stock Analysis: 57% Gain Amid Revenue and Margin ConcernsNews and Statistics - IndexBox
Imaging & Diagnostics Stocks Decline After Q4 2025 EarningsNews and Statistics - IndexBox
Lantheus Holdings Inc Stock (LNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):